August 28, Company Update Commerzbank Sector Conference Week

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "August 28, 2012. Company Update Commerzbank Sector Conference Week"

Transcription

1 August 28, 2012 Company Update Commerzbank Sector Conference Week

2 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing. These and other risks and uncertainties are detailed in the Company s Annual Report. 2

3 Components of the Business Technology-driven Alliances Proven HuCAL platform Novel Slonomics and Ylanthia technologies provide new opportunities Innovative Product Pipeline MOR103 phase 1b/2a data coming soon Four partner phase 2 studies complete in clinical programs AbD Serotec Emerging diagnostics business Research antibody catalog Financially Strong Sustainably cash-flow positive Strong balance sheet 3

4 Technology-driven Alliances 4

5 Proprietary Technology Platform Underpins Lucrative Alliances MorphoSys has successfully partnered its human antibody technology HuCAL with many of the leading pharmaceutical companies Lucrative model Makes MOR cash-flow positive Funds proprietary R&D Future upside from milestones & royalties Target MorphoSys Pharma partner HuCAL antibody drug candidate R&D funding Technology licence fees Milestones and royalties 5

6 Case Study: MorphoSys-Novartis One of the largest discovery alliances in the industry Term Through 2017, plus 2-year extension option Novartis pays Approx. 20m p.a. technology license fees Approx. 20m p.a. research funding Milestones and royalties on all resulting drugs Novartis gets Codevelopment option Excluded Preferred access to HuCAL for use in over 100 discovery programs Shared costs & profits (20% 50%) on codeveloped programs Most infectious disease targets 6

7 New Technologies Drive New Deals Slonomics Best technology for making protein libraries Exclusive access secured through acquisition of Sloning Biotechnology in 2010 Deals have already paid for acquisition Pfizer Novozymes Unnamed pharma Ylanthia Totally new antibody platform Higher quality antibodies, greater diversity, better biophysical properties, faster lead generation Opens new opportunities 7

8 Innovative Product Pipeline 8

9 74 Therapeutic Antibody Programs in the Pipeline Program Gantenerumab MOR103 (2 programs) CNTO888 CNTO1959 (2 programs) BHQ880 BYM338 NOV 3 NOV 4 MOR208 MOR202 BAY BI 1 CNTO3157 CNTO 5 NOV 5 NOV 6 OMP-18R5 OMP-59R5 PFE 1 21 Programs, incl. 1 co-dev with NOV 32 Programs, incl. 1 co-dev with NOV Partner Roche Target Amyloid-ß Indication Discovery Preclinic Alzheimer s Disease Rheumatoid Arthritis GM-CSF Multiple sclerosis Janssen/J&J MCP-1 (CCL-2) IPF Psoriasis Janssen/J&J IL23p19 RA Novartis DKK-1 Cancer Novartis Musculoskeletal Novartis not discl. Novartis Ophthalmology CD19 CLL CD38 MM Bayer Healthcare Mesothelin (ADC) Cancer BI not discl. Janssen/J&J Asthma Janssen/J&J Inflammation Novartis Inflammation Novartis Cancer OncoMed Fzd 7 Cancer OncoMed Notch 2 Cancer Pfizer Cancer Various Partners - Various Indications Various Partners - Various Indications Phase 1 Phase 2 Phase 3 66 Partnered Programs 8 Proprietary Programs 9

10 Recent Partnered Pipeline Progress Gantenerumab Phase 2 trial expanded to potentially pivotal phase 2/3 CNTO1959 Comparison phase 2 study with Stelara in ~250 patients BYM338 Phase 2 in sporadic inclusion body myositis completed OMP-18R5 / OMP-59R5 Preclinical and clinical data presented at several scientific conferences BAY US orphan drug status in mesothelioma 10

11 Partner Program Case Study Gantenerumab: Alzheimer s Disease The Drug High affinity HuCAL antibody targeting amyloid-β Binds N-terminus and mid-section of Aβ40-42 peptide Large Market and Unmet Need AD is estimated to affect 25 million people worldwide High unmet medical need, no curative treatments available Clinical Development Phase 1, in patients: Completed Gantenerumab: Rapid, dose-dependent reduction of plaque: 16-36% reduction within 7 months Bapineuzumab: 9% plaque reduction over 18 months Pivotal Phase 2/3 Study Ongoing 770 prodromal patients, 2 doses, placebo-controlled 104 weeks on drug CDR-SOB, ADAS-COG, change in brain amyloid Favorable outcome to the trial could be used by Roche to support a marketing application 11

12 Recent Progress with Proprietary Portfolio MOR103 Data from completed phase 1b/2a in September 2012 Data for subcutaneous formulation Trial in MS ongoing MOR 208 Enrollment in phase 1 trial in CLL completed Study data expected in Q Presentation of preclinical combination therapy data at ASCO MOR202 Phase 1 trial in multiple myeloma ongoing 12

13 MOR103 A Novel Anti-Inflammatory Antibody The Drug Ultra-high affinity HuCAL IgG1 targeting GM-CSF GM-CSF is a key inflammatory mediator in rheumatoid arthritis and other inflammatory conditions Potential to become first and best-in-class anti-gm-csf mab Large Market and Unmet Need Revenues with approved biologics in rheumatoid arthritis over $12bn 50% of RA patients do not respond to anti-tnf therapy beyond 2 years Potential in MS, osteoarthritis, pain, asthma, COPD Intellectual Property Exclusive license to a US patent covering anti-gm-csf antibodies for the treatment of chronic inflammatory conditions US patent on MOR103 composition of matter 13

14 MOR103 A Novel Drug in a Clinically Validated Pathway Clinical Validation of Pathway Phase 2 data for mavrilimumab, antibody vs. GM-CSF receptor, provides clinical validation of the pathway in rheumatoid arthritis Clinical Development of MOR103 Phase 1, in healthy volunteers: MOR103 generally safe and well-tolerated Phase 1b/2a, in RA patients: Fully recruited, data expected in September 2012 Phase 1, PK study for sc administration: Initiated Q1 2012, data expected in September 2012 Phase1b, safety study in MS patients: Initiated Q4 2011, data expected in

15 MOR208 (XmAb5574) A Novel Anti-Cancer Antibody The Drug Humanized, high affinity anti-cd19 antibody Exclusive license from Xencor Antibody comprises a proprietary Xencor modification of the Fc part of the antibody leading to rapid and sustained B-cell depletion Large Market and Unmet Need High unmet medical need in NHL, CLL & ALL Revenues with approved drugs in B cell malignancies (CLL, NHL & ALL) exceed $5bn Relapsing patients have only limited treatment options In ALL no antibody therapy at all exists and current chemotherapy regimens are associated with very unfavorable safety profile 15

16 MOR208 (XmAb5574) A Highly Competitive Novel Antibody Clinical Validation of Pathway Phase 2 data for blinatumomab validate CD19 as target for B-cell malignancies MOR208 Has An Attractive Competitive Profile Expect convenient dosing schedule Straightforward manufacturing Potential for good safety profile Significantly increased ADCC compared to unmodified antibody Clinical Development Preclinical Data show synergistic effects on target cell killing in combination therapies with existing drugs Phase 1, in 30 relapsed or refractory CLL/SLL patients: Recruitment completed Data expected in Q Phase 2: Trials in B cell malignancies starting Q

17 MOR202 A Novel Antibody for Multiple Myeloma The Drug High affinity HuCAL antibody targeting CD38 Large Market and Unmet Need Revenues with approved drugs in MM exceed $2bn MM median survival is approximately 3-5 years Competitive Profile Preclinical data show strong synergy in combinations of MOR202 with Velcade or Revlimid Clinical Development Phase 1, in relapsed or refractory MM patients: ongoing Phase 2a, monotherapy extension Phase 1b, MOR202 + Velcade Phase 1b, MOR202 + Revlimid Up to 82 patients, at sites in Germany and Austria 17

18 AbD Serotec 18

19 AbD Serotec Segment Complements Therapeutic Business Research Activities Catalogue of 15,000+ products Stable and recurring cash flows Customers comprise universities, government bodies, life science companies Website, ecommerce HuCAL Diagnostic Applications Custom antibody generation Using proprietary technologies to deliver superior Dx antibodies Future upside via royalties Working with over 20 Dx companies 19

20 Strong Financials 20

21 Key Financials in million 2011 Guidance 2012 H Group Revenues Total Operating Expenses COGS Funded R&D Proprietary R&D (incl. technology development) 36.8 Sales, General & Administrative Expenses 24.6 EBIT 10.1 Cash & Marketable Securities and Interest-bearing Assignable Loans (at end of period) (1.9)

22 Shareholdings Shares issued: 23,252,972 (June 30, 2012) Treasury stock: 255,415 (June 30, 2012) 22

23 Milestones in 2012 Proprietary Portfolio MOR103 Phase 1b/2a data in RA MOR208 Phase 1 data in CLL MOR202 to continue enrollment in phase 1 trial in MM patients Partnered Pipeline Several phase 2 studies will complete in 2012* CNTO888 (Janssen Biotech, IPF) BHQ880 (Novartis, oncology) BYM338 (Novartis, musculoskeletal diseases) Novartis (n.d.) 1-3 new INDs Technology-driven alliances New diagnostic products from AbD Serotec * MorphoSys estimates based on publicly-available information 23

24 Thank You Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR Phone +49 (0)89 / Fax +49 (0)89 / Dr. Simon Moroney Chief Executive Officer Phone +49 (0)89 / Fax +49 (0)89 / HuCAL, HuCAL GOLD, HuCAL PLATINUM, CysDisplay, RapMAT, aryla and Ylanthia and 100 billion high potentials are registered trademarks of MorphoSys AG Slonomics is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

Jefferies 2012 Global Healthcare Conference. June 8, 2012

Jefferies 2012 Global Healthcare Conference. June 8, 2012 Jefferies 2012 Global Healthcare Conference June 8, 2012 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Eigenkapitalforum 2013. Company Update November 12, 2013

Eigenkapitalforum 2013. Company Update November 12, 2013 Eigenkapitalforum 2013 Company Update November 12, 2013 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

9. WestLB Deutschland Conference. Frankfurt November 16, 2011

9. WestLB Deutschland Conference. Frankfurt November 16, 2011 9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Deutsches Eigenkapitalforum. Frankfurt November 22, 2011

Deutsches Eigenkapitalforum. Frankfurt November 22, 2011 Deutsches Eigenkapitalforum Frankfurt November 22, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011 Kempen & Co 4 th Healthcare/Life Sciences Conference Brussels March 29, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included

More information

UBS Global Life Sciences Conference 2011. New York September 19, 2011

UBS Global Life Sciences Conference 2011. New York September 19, 2011 UBS Global Life Sciences Conference 2011 New York September 19, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the

More information

Commerzbank Sector Conference. Frankfurt August 30, 2011

Commerzbank Sector Conference. Frankfurt August 30, 2011 Commerzbank Sector Conference Frankfurt August 30, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Commerzbank Sector Conference Week. Company Update August 27, 2013

Commerzbank Sector Conference Week. Company Update August 27, 2013 Commerzbank Sector Conference Week Company Update August 27, 2013 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Company Update. March 2011

Company Update. March 2011 Company Update March 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various

More information

Deutsche Bank 36th Annual Health Care Conference. Boston May 3, 2011

Deutsche Bank 36th Annual Health Care Conference. Boston May 3, 2011 Deutsche Bank 36th Annual Health Care Conference Boston May 3, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the

More information

Q3 2015 Conference Call

Q3 2015 Conference Call November 4, 2015 Q3 2015 Conference Call 1 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements

More information

Société Générale: 6th Mid & Small Caps Conference. Nice May 5, 2011

Société Générale: 6th Mid & Small Caps Conference. Nice May 5, 2011 Société Générale: 6th Mid & Small Caps Conference Nice May 5, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the

More information

12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma

12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma 12. November 2013 Jan Endell From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma The MorphoSys Pipeline 21 Clinical Programs, 82 Total Program

More information

Rodman & Renshaw Annual Global Investment Conference. September 13, 2010

Rodman & Renshaw Annual Global Investment Conference. September 13, 2010 Rodman & Renshaw Annual Global Investment Conference September 13, 2010 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in

More information

Rodman & Renshaw 5th Annual Global Healthcare Conference. Monte Carlo May 2008

Rodman & Renshaw 5th Annual Global Healthcare Conference. Monte Carlo May 2008 Rodman & Renshaw 5th Annual Global Healthcare Conference Monte Carlo May 2008 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included

More information

MorphoSys Proprietary Development Update

MorphoSys Proprietary Development Update September 8, 2015 MorphoSys Proprietary Development Update 1 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Company Update. March 2012

Company Update. March 2012 Company Update March 2012 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various

More information

Bank of America Merrill Lynch Global Healthcare Conference 2015. Company Update. September 17, 2015

Bank of America Merrill Lynch Global Healthcare Conference 2015. Company Update. September 17, 2015 Bank of America Merrill Lynch Global Healthcare Conference 2015 Company Update September 17, 2015 1 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially

More information

2015 Wells Fargo Securities Healthcare Conference. Company Update. September 9, 2015

2015 Wells Fargo Securities Healthcare Conference. Company Update. September 9, 2015 2015 Wells Fargo Securities Healthcare Conference Company Update September 9, 2015 1 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those

More information

J.P. Morgan Healthcare Conference. Company Update January 14, 2016

J.P. Morgan Healthcare Conference. Company Update January 14, 2016 J.P. Morgan Healthcare Conference Company Update January 14, 2016 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

Annual Report 2014. ENGINEERING the. Medicines. of TOMORROW

Annual Report 2014. ENGINEERING the. Medicines. of TOMORROW Annual Report 2014 ENGINEERING the Medicines of TOMORROW Product Pipeline MorphoSys s Product Pipeline, as of 31 December 2014 PHASE 1 PHASE 2 PHASE 3 9 Programs 10 Programs 3 Programs Additionally, MorphoSys

More information

ANNUAL REPORT 2013. the of

ANNUAL REPORT 2013. the of ANNUAL REPORT 2013 the of Product Pipeline MorphoSys s Product Pipeline, as of 31 December 2013 Program Partner Indication Phase 1 Phase 2 Phase 3 Market MOR103 GSK Rheumatoid arthritis Multiple sclerosis

More information

ANNUAL REPORT 2012 ANTI BODIES CON NECT

ANNUAL REPORT 2012 ANTI BODIES CON NECT ANNUAL REPORT 2012 ANTI BODIES CON NECT Product Pipeline MORPHOSYS S PRODUCT PIPELINE AS OF 31 DECEMBER 2012 Program / Partner Indication Discovery Preclinic Phase 1 Phase 2 Phase 3 Market MOR208 Cancer

More information

MorphoSys AG Q3 2015 Conference Call Text November 4, 2015 The spoken word shall prevail.

MorphoSys AG Q3 2015 Conference Call Text November 4, 2015 The spoken word shall prevail. MorphoSys AG Q3 2015 Conference Call Text November 4, 2015 The spoken word shall prevail. Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR, MorphoSys AG Good afternoon, good morning and

More information

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR, MorphoSys AG

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR, MorphoSys AG MorphoSys AG Pipeline Update - Conference Call Text September 8, 2015 The spoken word shall prevail. Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR, MorphoSys AG Safe Harbor Good afternoon

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

2nd Interim Report January June 2015

2nd Interim Report January June 2015 2nd Interim Report January June 2015 Contents MorphoSys Group: 2nd Interim Report January June 2015 3 SUMMARY 4 INTERIM GROUP MANAGEMENT REPORT 4 BUSINESS ENVIRONMENT AND ACTIVITIES 5 COMMERCIAL DEVELOPMENT

More information

Annual Report 2010. Antibodies for Life

Annual Report 2010. Antibodies for Life Annual Report 2010 Antibodies for Life Key Figures (IFRS) MORPHOSY S GROUP (in million, if not stated otherwise) 12/31/2010 12/31/2009 12/31/2008 12/31/2007 12/31/2006 RESULTS Revenues 87.0 81.0 71.6 62.0

More information

MRC Technology Centre for Therapeutics Discovery

MRC Technology Centre for Therapeutics Discovery MRC Technology Centre for Therapeutics Discovery fast-tracking discovery and development of novel drugs from academia Dr Duncan Young Business Development Manager UbiFrance Symposium, October 2012 established

More information

SEPTEMBER 2015 MICHAEL OREDSSON,CEO

SEPTEMBER 2015 MICHAEL OREDSSON,CEO SEPTEMBER 2015 MICHAEL OREDSSON,CEO 2 INVESTMENT HIGHLIGHTS Combines the valuable n-coder library of 30 billion antibodies with the proprietary F.I.R.S.T technology to identify the right antibodies for

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

Stefanie Urlinger, Director R&D, MorphoSys AG. Making fully human antibody drugs from synthetic antibody libraries

Stefanie Urlinger, Director R&D, MorphoSys AG. Making fully human antibody drugs from synthetic antibody libraries Stefanie Urlinger, Director R&D, MorphoSys AG Making fully human antibody drugs from synthetic antibody libraries Introduction: MorphoSys MorphoSys An Overview MorphoSys is a leader in the discovery &

More information

Technology into Products

Technology into Products Annual Report 2007 MorphoSys AG A n n u a l r e p o r t 20 07 Financial Calendar Turning Technology into Products February 28, 2008 Year-End 2007 Results MorphoSys s proprietary HuCAL GOLD antibody library

More information

Medical Therapies Limited EGM Presentation

Medical Therapies Limited EGM Presentation Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for

More information

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR, MorphoSys AG

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR, MorphoSys AG MorphoSys AG Q3 2014 Conference Call Text 7 November 2014 The spoken word shall prevail. Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR, MorphoSys AG Slide 2: Safe Harbor Good afternoon

More information

Building innovative drug discovery alliances. Profitable. Growth Go

Building innovative drug discovery alliances. Profitable. Growth Go Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains

More information

Genm ab 2007 Annual R epor 2007 Annual Report t

Genm ab 2007 Annual R epor 2007 Annual Report t 2007 Annual Report Clinical Product Pipeline Program Phase I/II Phase II Phase III HuMax-CD20 Chronic lymphocytic leukemia (B-CLL) Non-Hodgkin s lymphoma (NHL) Rheumatoid arthritis (RA) Methotrexate ref.

More information

Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland

Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland Tone Kvåle, Chief Financial Officer Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway - www.nordicnanovector.com

More information

ANNUAL REPORT 2009 BUILDING A LEADING ANTIBODY PIPELINE

ANNUAL REPORT 2009 BUILDING A LEADING ANTIBODY PIPELINE ANNUAL REPORT 2009 BUILDING A LEADING ANTIBODY PIPELINE key figures (ifrs) morphosys group (in million, if not stated otherwise) 12/31/2009 12/31/2008 12/31/2007 12/31/2006 12/31/2005 RESULTS Revenues

More information

TERM SHEET EXAMPLE. 1 P age

TERM SHEET EXAMPLE. 1 P age 1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with

More information

ExplorE... Annual Report 2011

ExplorE... Annual Report 2011 ExplorE... Annual Report 2011 Product Pipeline MoRphoSyS S produc t pipeline AS of december 31, 2011 program / partner indication discovery preclinic phase 1 phase 2 phase 3 Market MOR103 Rheumatoid arthritis

More information

MOLOGEN AG German Equity Forum 2015

MOLOGEN AG German Equity Forum 2015 German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies

More information

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

Affitech A/S reports financial result for the first six months of 2012

Affitech A/S reports financial result for the first six months of 2012 Release no. 23/2012 Affitech A/S reports financial result for the first six months of 2012 Clinical trials sites initiated in Russia in late June 2012 by Affitech s collaboration partner IBC Generium for

More information

Company Presentation

Company Presentation Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars

More information

Genmab A/S Genmab Ltd. Genmab, Inc. Genmab MN, Inc.

Genmab A/S Genmab Ltd. Genmab, Inc. Genmab MN, Inc. 2009 Annual Report PRE-CLINICAL AND CLINICAL PRODUCT PIPELINE AS OF MARCH 2, 2010 Development Phase Product Disease Indications Pre-Clinical I I/II II III Ofatumumab 17 studies Partner: GSK Chronic lymphocytic

More information

A disease and antibody biology approach to antibody drug discovery

A disease and antibody biology approach to antibody drug discovery A disease and antibody biology approach to antibody drug discovery Björn Frendéus, PhD VP, Preclinical research Presenter: Björn Frendéus Date: 2011-11-08 1 Antibodies have revolutionized Cancer Treatment!

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

Valneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013

Valneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013 Valneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013 Revenue Ahead of Guidance and Cash Target Met in First year Following Merger Total revenues and grants

More information

argen-x Business Update and First Half 2014 Results

argen-x Business Update and First Half 2014 Results argen-x Business Update and First Half 2014 Results 27 August 2014 Breda, the Netherlands / Ghent, Belgium argen-x N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on

More information

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd.

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Oncology Strategy and Acquisition Significance 1 Commitment to Oncology Entering the Oncology Area Globally External

More information

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:

More information

Global Monoclonal Antibodies Pipeline Insight 2015

Global Monoclonal Antibodies Pipeline Insight 2015 Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who

More information

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune

More information

HuCAL Custom Monoclonal Antibodies

HuCAL Custom Monoclonal Antibodies HuCAL Custom Monoclonal Antibodies Highly Specific Monoclonal Antibodies in just 8 Weeks PROVEN, HIGHLY SPECIFIC, HIGH AFFINITY ANTIBODIES IN 8 WEEKS WITHOUT HuCAL PLATINUM IMMUNIZATION (Human Combinatorial

More information

Health Care Worldwide. Citi - European Credit Conference September 24, 2015 - London

Health Care Worldwide. Citi - European Credit Conference September 24, 2015 - London Health Care Worldwide Citi - European Credit Conference September 24, 2015 - London Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties.

More information

Welcome to the Launch of Biocon s Breakthrough Innovation. For Psoriasis. Treatment

Welcome to the Launch of Biocon s Breakthrough Innovation. For Psoriasis. Treatment Welcome to the Launch of Biocon s Breakthrough Innovation For Psoriasis Treatment PRESS MEET Bangalore, August 10, 2013 Autoimmune Diseases are on the Rise Globally Autoimmune Disease Segment includes

More information

A Case for Cure: Drug Portfolio Analysis. Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal

A Case for Cure: Drug Portfolio Analysis. Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal A Case for Cure: Drug Portfolio Analysis Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal Executive Summary Our team recommends. A Recombinant Protein for treatment of Multiple

More information

Biotest AG Welcome to our Analysts conference

Biotest AG Welcome to our Analysts conference Biotest AG Welcome to our Analysts conference 0 Agenda Plasma proteins Biotherapeutics Diagnostics Key Financials 1 Biotest at a glance Further growth by woldwide sales Sales Q1-Q3 2008: 323.0 m Full year

More information

Health Care Worldwide

Health Care Worldwide Health Care Worldwide Barclays European High Yield and Leveraged Finance Conference October 30, 2014 London Barclays European High Yield and Leveraged Finance Conference, October 30, 2014 Copyright Page

More information

argen-x Reports Fourth Quarter Business Update And Full Year 2014 Financial Results

argen-x Reports Fourth Quarter Business Update And Full Year 2014 Financial Results argen-x Reports Fourth Quarter Business Update And Full Year 2014 Financial Results Management to host conference call today at 6 pm CET / 1 pm EDT 18 March 2015 Breda, the Netherlands / Ghent, Belgium

More information

Health Care Worldwide

Health Care Worldwide Health Care Worldwide Credit Suisse Global Credit Products Conference September 18, 2014 Miami Credit Suisse Global Credit Products Conference, September 18, 2014 Copyright Page 1 Safe Harbor Statement

More information

EVT Execute & EVT Innovate World-class drug discovery

EVT Execute & EVT Innovate World-class drug discovery EVT Execute & EVT Innovate World-class drug discovery Evotec AG, First Quarter Report 2015, 12 May 2015 Forward-looking statements Information set forth in this presentation contains forward-looking statements,

More information

Transforming Molecules into Breakthrough Therapies. Timothy Wright, M.D. Global Head Pharma Development Investor Day London, 22 November 2013

Transforming Molecules into Breakthrough Therapies. Timothy Wright, M.D. Global Head Pharma Development Investor Day London, 22 November 2013 Transforming Molecules into Breakthrough Therapies Timothy Wright, M.D. Global Head Pharma Development Investor Day London, 22 November 2013 Disclaimer This presentation contains forward-looking statements

More information

A career on the science park

A career on the science park A career on the science park Onno van de Stolpe December 2014 Copyright 2014 Galapagos NV 1987 MOGEN Agricultural biotech pioneer Design of transgenic plants with improved traits Close link with Prof Schilperoort

More information

Biotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG

Biotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG Company Presentation July 2013 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and its

More information

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 XENOPORT INC FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 Address 3410 CENTRAL EXPRESSWAY SANTA CLARA, CA 95051 Telephone 4086167200 CIK 0001130591 Symbol XNPT SIC Code

More information

HuCAL Custom Monoclonal Antibodies

HuCAL Custom Monoclonal Antibodies HuCAL Custom Monoclonal HuCAL Custom Monoclonal Antibodies Highly Specific, Recombinant Antibodies in 8 Weeks Highly Specific Monoclonal Antibodies in Just 8 Weeks HuCAL PLATINUM (Human Combinatorial Antibody

More information

Biotest Group. H1 2014 Conference call 12 August 2014

Biotest Group. H1 2014 Conference call 12 August 2014 Biotest Group H1 2014 Conference call 12 August 2014 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents

More information

MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME

MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME FOR IMMEDIATE RELEASE MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME - $185 Million Collaboration to Determine All Human Protein Interactions And Decipher Biochemical Pathways

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

Innovating antibodies, improving lives

Innovating antibodies, improving lives ANNUAL REPORT 2014 Innovating antibodies, improving lives Genmab A/S CVR No. 21 02 38 84 DIRECTORS REPORT TABLE OF CONTENTS PRODUCTS Table of Contents Directors Report page 1 Genmab At-A-Glance 1 Shareholder

More information

Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop

Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop This presentation contains certain forward-looking statements. These forward-looking statements

More information

Flamel Technologies Provides Update on Corporate Progress

Flamel Technologies Provides Update on Corporate Progress Flamel Technologies Provides Update on Corporate Progress Clinical Programs Continue to Move Forward Outlines Full Year 2016 Revenue Guidance Lyon, France January 8, 2016 - Flamel Technologies (NASDAQ:

More information

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies PRESS RELEASE Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies Servier Also Enters Into Exclusive Global

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011

More information

Genzyme s Multiple Sclerosis Franchise Featured at AAN

Genzyme s Multiple Sclerosis Franchise Featured at AAN PRESS RELEASE Genzyme s Multiple Sclerosis Franchise Featured at AAN - Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs - Paris, France March 13, 2013 Sanofi (EURONEXT:

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

Peter Kellogg, CFO. Goldman Sachs Laguna Niguel,, CA June 14, 2006. Fair Disclosure: Under Reg

Peter Kellogg, CFO. Goldman Sachs Laguna Niguel,, CA June 14, 2006. Fair Disclosure: Under Reg Peter Kellogg, CFO Goldman Sachs Laguna Niguel,, CA Fair Disclosure: Under Reg FD, the SEC has set out a series of regulations regarding selective disclosure of material non-public information. In an effort

More information

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties

More information

EVT Execute & EVT Innovate Leading drug discovery

EVT Execute & EVT Innovate Leading drug discovery EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking

More information

Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS. Paul

Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS. Paul Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS Paul Antares Mission: To develop and commercialize self-administered parenteral medicines

More information

INTERIM REPORT, 1 January - 30 June 2003

INTERIM REPORT, 1 January - 30 June 2003 PRESS RELEASE, 9 July INTERIM REPORT, 1 January - 30 June In May, Medivir reached a licensing agreement on MIV-210 with GlaxoSmithKline; EUR 6 m was received upon signing and up to EUR 86 m on the achievement

More information

RECORD OF COMMERCIAL SUCCESS

RECORD OF COMMERCIAL SUCCESS MULTIPLE SCLEROSIS HEMOPHILIA CD-20 THERAPIES RECORD OF COMMERCIAL SUCCESS 5 5 Note: Rituxan and Gazyva are in collaboration with Roche Revenues ($B) Non-GAAP Diluted EPS ($) +18% CAGR +24% CAGR 12.09

More information

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.

More information

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster

More information

Vectura Group plc. Annual Report and Accounts 2015

Vectura Group plc. Annual Report and Accounts 2015 RNS Number : 1783Q Vectura Group plc 15 June 2015 15 June 2015 Vectura Group plc Annual Report and Accounts 2015 In accordance with the Listing Rule 9.6.1, a copy of the following document has been submitted

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Commerzbank German Investment Seminar January 11/12, 2016 For detailed financial information please see our annual/quarterly reports and/or conference call materials

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September

More information

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo to Acquire Ambit Biosciences For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please

More information

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Brochure More information from http://www.researchandmarkets.com/reports/2904677/ Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Pleural Mesothelioma - Pipeline Review,

More information

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, 11 March 2008 Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, France, March 11, 2008 Transgene (Euronext Paris: FR0005175080) announces

More information

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019 Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive

More information

PROMETIC LIFE SCIENCES INC.

PROMETIC LIFE SCIENCES INC. PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.

More information

using the fully human ADLib system

using the fully human ADLib system Company Research and Analysis Report FISCO Ltd. http://www.fisco.co.jp 伪 伪 Focusing on improving technology to obtain antibodies using the fully human ADLib system (4583) (subsequently, the company ) is

More information